NEWS
Crown Laboratories and Revance Announce Entry Into Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced a merger agreement, with Crown offering to acquire all outstanding Revance shares for $6.66 per share in cash. This represents a total enterprise value of $924 million and a 89% premium over Revance's closing price on August 9, 2024. The merger aims to create a leading, innovative aesthetics and skincare company, combining Crown's skincare products with Revance's aesthetics offerings.
The combined company will feature flagship brands including DAXXIFY®, RHA® Collection, SkinPen®, PanOxyl®, Blue Lizard®, and StriVectin®. It will have global commercialization capabilities, covering over 10,000 medical professionals and various retail channels. The transaction is expected to close by year-end, subject to stock
The combined company will feature flagship brands including DAXXIFY®, RHA® Collection, SkinPen®, PanOxyl®, Blue Lizard®, and StriVectin®. It will have global commercialization capabilities, covering over 10,000 medical professionals and various retail channels. The transaction is expected to close by year-end, subject to stock
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1413Followers
80Following
10KVisitors
Follow